IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy
Oct 24, 2019
Oct 24, 2019 |
10 min
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
City of Hope receives US DoD grant with upside for Imugene
Oct 23, 2019
Oct 23, 2019 |
4 min
A US Department of Defense Grant has been awarded to renowned City of Hope researchers to fund research into gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.
Imugene to demonstrate the benefits of combination tumor treatment
Oct 21, 2019
Oct 21, 2019 |
3 min
Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.
Australia’s top biotechs descend on Queenstown for the 2019 Bioshares Summit
Jul 25, 2019
Jul 25, 2019 |
13 min
Queenstown, the New Zealand extreme sport mecca, hosts the annual Bioshares Biotech Summit, gathering together some of the best long-standing and emerging biotech companies in the country to talk all things trials, tribulations and potential cures for cancer.
IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking
Jul 25, 2019
Jul 25, 2019 |
12 min
Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.
